Literature DB >> 3815399

Phase II trial of esorubicin in patients with advanced melanoma.

S Frustaci, G Gasparini, E Galligioni, U Tirelli, N Di Pietro, D Crivellari, G Lo Re, S Monfardini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3815399

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).

Authors:  H Hochster; M Hunt; M Green; D Parkinson; T Smith
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

2.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; M L Berman
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

3.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; E Yordan; J Beecham
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.